Galectin -3: an independent cardiac marker of left ventricular (LV) remodeling in chronic heart failure

Mario Leesha Fernando; Santhi Silambanan

doi:10.51248/.v43i4.3343

Authors

Mario Leesha Fernando
Santhi Silambanan

DOI:

https://doi.org/10.51248/.v43i4.3343

Keywords:

Galectin -3 (Gal-3), Brain Natriuretic Peptide (BNP), Chronic Heart failure (CHF), Left Ventricular Dysfunction (LVD), New York Heart Association (NYHA), Left Ventricular Ejection Fraction (LVEF)

Abstract

Introduction and Aim: Heart failure (HF) with increased morbidity and mortality is a critical condition where the cardiac pumping capacity fails to meet up with the body’s demand. Its development is silent due to slow, progressive remodeling presenting with symptoms later. Brain Natriuretic peptides (BNP) denotes ventricular loading status which do not reveal other mechanisms whereas a novel marker Galectin-3 (Gal-3) provides information about cardiac structural changes which includes inflammation, fibrosis, remodeling for guiding treatment. Research studies demonstrated that there is upregulation of Galectin- 3 in both acute and chronic heart failure (CHF) individuals. The objectives of our study were to compare Galectin- 3 levels in moderate and severe LVD CHF patients and determine whether serum Galectin -3 can be used as an independent cardiac marker of ventricular structural remodeling in such HF individuals.

Materials and Methods: 80 patients between 20 - 80 years diagnosed with CHF using Framingham criteria with ejection fraction (EF) of 45% and classified into two groups:(i) moderate LVD and (ii) severe LVD. Those with abnormal kidney functions were excluded. Comparison was done between serum Galectin - 3 and BNP; Gal- 3 was determined to be an independent marker of structural remodeling of LV between the two categories.

Results: Galectin-3 and BNP were significantly increased in HF with severe LVD than moderate LVD. Multivariate linear regression showed Galectin-3 as an independent predictor of LV remodeling with respect to changes in LV end- diastolic dimension with statistically significant p 0.001 whereas BNP did not show any such significance.

Conclusion: Galectin -3 and BNP levels were elevated in severe LV dysfunction than moderate LVD and concluded that Gal-3 is an independent cardiac biomarker of LV remodeling in Chronic heart failure.

Author Biographies

Mario Leesha Fernando

Department of Biochemistry, Bhaarath Medical College and hospital (BIHER), Chennai, Tamil Nadu, India

Santhi Silambanan

Sri Ramachandra Medical College and Research Institute, Chennai, Tamil Nadu, India

References

Subramanian, R., Shiek, A., Meyyappan, C. Efficacy of enhanced external counter pulsation in improving six minutes’ walk test in heart failure patients. Biomedicine. 2022 May 1;42(2):274-279.

Padma, V., Raja, R. B., Nair, A.B. Cardiac injury and COVID-19: A Review on available present-day literature. Biomedicine. 2020;40(4):420-428.

Beattie, J.M., Death by oxymoron? The enigma of heart failure with preserved ejection fraction, Curr Opin Support Palliat Care 2014; 8:1-3.

Loffredo, F.S., Nikolova, A.P., Pancoast, J.R., Lee, R.T. Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium. Circ Res 2014;115:97-107.

Jong, P., Yusuf, S., Rousseau, M.F., Ahn, S.A., Bangdiwala, S.I., Effect of Enalapril on 12- year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003; 361:1843-1848.

Schocken, D.D., Benjami, E.J., Fonarow, G.C., Krumholz, H.M., Levy, D., Mensah, G.A., et al., Prevention of heart failure: a scientific statement from the American Heart Association councils on epidemiology and prevention, clinical cardiology, cardiovascular nursing and high blood pressure research; quality of care and outcomes research interdisciplinary working group; and functional genomics and translational biology interdisciplinary working group. Circulation 2008; 117: 2544-2565.

de Couto, G., Ouzaounian, M., Liu, P.P. Early detection of myocardial dysfunction and heart failure. Nat Rev Cardiol 2010; 7: 334-344.

Franke, J., Frankenstein, L., Schellberg, D., Bajrovic, A., Wolter, J.S., Ehlermann, P., et al., Is there an additional benefit of serial NT-proBNP measurements in patients with stable chronic heart failure receiving individually optimized therapy? Clin Res Cardiol. 2011; 100(12):1059-1067.

Böhm, M., Voors, A.A., Ketelslegers, J.M., Schirmer, S.H., Turgonyi, E., Bramlage, P., et al., Biomarkers: optimizing treatment guidance in heart failure. Clin Res Cardiol. 2011; 100(11):973-981.

de Boer, R.A., Yu, L., van Veldhuisen, D.J., Galectin-3 in cardiac remodeling and heart failure, Curr Heart Fail Rep. 2010;7: 1-8.

Bayes-Genis, A., de Antonio, M., Vila, J., Peñafiel, J., Galán, A., Barallat, J., et al., Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol. 2014; 63(2):158-166.

Morrow, D., O'Donoghue, M., Galectin-3 in cardiovascular disease. J Am Coll Cardiol. 2012, 60 (14) 1257-1258.

Hrynchyshyn, N., Jourdain, P., Desnos, M., Diebold, B., Funck, F., Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure. Arch Cardiovasc Dis. 2013;106(10):541-546.

Lok, D.J., Lok, S.I., Bruggink-André de la Porte, P.W., Badings, E., Lipsic, E., van Wijngaarden, J., et al., Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol. 2013;102(2):103-110.

Krumholz, H.M., Chen, Y.T., Wang, Y., Vaccarino, V., Radford, M.J., Horwitz, R.I., Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J. 2000; 139(1 Pt 1):72-77.

Milting, H., Ellinghaus, P., Seewald, M., Cakar, H., Bohms, B., Kassner, A., et al., Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant. 2008; 27(6):589-596.

Chen, K., Jiang, R.J., Wang, C.Q., Yin, Z.F., Fan, Y.Q., Cao, J.T., et al., Predictive value of plasma galectin-3 in patients with chronic heart failure. Eur Rev Med Pharmacol Sci. 2013; 17(8):1005-1011.

Tang, W.H., Shrestha, K., Shao, Z., Borowski, A.G., Troughton, R.W., Thomas, J.D., et al., Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol. 2011;108(3):385-390.

van Kimmenade, R.R., Januzzi, J.L. Jr., Ellinor, P.T., Sharma, U.C., Bakker, J.A., Low, A.F., et al., Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006;48(6):1217-1224.

McKay, R.G., Pfeffer, M.A., Pasternak, R.C., Markis, J.E., Come, P.C., Nakao, S., et al., Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation. 1986;74(4):693-702.

Sharma, U.C., Pokharel, S., van Brakel, T.J., van Berlo, J.H., Cleutjens, J.P., Schroen, B., et al., Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.Circulation. 2004;110(19): 3121-3128.

Solomon, S.D., Skali, H., Anavekar, N. S., Bourgoun, M., Barvik, S., Ghali, J. K., et al., Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction. Circulation. 2005;111(25):3411-3419.

White, H.D., Norris, R.M., Brown, M.A., Brandt, P.W., Whitlock, R.M., Wild, C.J., Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987; 76(1):44-51.

Lee, T.H., Hamilton, M.A., Stevenson, L.W., Moriguchi, J.D., Fonarow, G.C., Child, J.S., et al., Impact of left ventricular cavity size on survival in advanced heart failure. Am J Cardiol. 1993; 72(9):672-676.

Wong, M., Staszewsky, L., Latini, R., Barlera, S., Glazer, R., Aknay, N., et al., Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. J Am Coll Cardiol. 2004;43(11):2022-2027.

Sharma, K., Kass, D.A., Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res. 2014;115(1):79-96.

Toprak, G., Yüksel, H., Demirpençe Ö Islamoglu, Y., Evliyaoglu, O., Mete, N., Fibrosis in heart failure subtypes. Eur Rev Med Pharmacol Sci. 2013;17(17):2302-2309.

Calvier, L., Miana, M., Reboul, P., Cachofeiro, V., Martinez-Martinez, E., de Boer, R.A., et al., Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol. 2013; 33(1):67-75.